Using 68Ga-HA-DOTATATE PET/CT to Diagnose Neuroendocrine Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of 68Ga-HA-DOTATATE PET/CT imaging in diagnosing somatostatin positive neuroendocrine tumors compared to conventional imaging methods such as CT, MRI, and other PET scans. It aims to determine the utility of this imaging technique in the primary workup of suspected neuroendocrine tumors and in the surveillance of completely resected tumors. Additionally, the study will assess its role in localizing functioning neuroendocrine tumors like insulinoma and gastrinoma. Participants will undergo imaging to compare results with standard diagnostic approaches.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female. If female of child-bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test will be required.
2. Age greater than or equal to 18 years.
3. Able and willing to follow instructions and comply with the protocol.
4. Provide written informed consent prior to participation in the study.
5. Clinically suspected (patients presenting with symptom(s) suggestive of carcinoid syndrome or biochemically suggestive of Neuroendocrine Tumor) or Biopsy proven Neuroendocrine Tumor

Exclusion Criteria:

1. Nursing or pregnant females.
2. Age less than 18 years.
3. Surgery in the area of interest within the preceding 2 months.

Where it's running

• Foothills Medical Center 1403 29 St NW
  Calgary, Alberta, Canada Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-guided diagnosis and management of pancreatic cysts using endoscopic ultrasound

  This project will test an AI tool that uses EUS images plus CT/MRI and lab data to help doctors tell mucinous from non-mucinous pancreatic cysts and guide care for adults with pancreatic cystic lesions.

  Recruiting Huazhong University of Science and Technology · Wuhan, Hubei and 1 other locations · NCT07463872

• Evaluating MT-4561 in Patients with Advanced Solid Tumors

  This study is testing a new drug called MT-4561 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 6 sites Phase 1/2 Tanabe Pharma America, Inc. · Los Angeles, California and 5 other locations · NCT06943521

• Structured lipid nutrition for people with pancreatic cancer

  Try a structured lipid medical food (Encala) to help people with pancreatic cancer who have trouble absorbing fat.

  Recruiting at 2 sites Children's Hospital of Philadelphia · Philadelphia, Pennsylvania and 1 other locations · NCT07554560

• [177Lu]Lu-DOTA-TATE plus octreotide LAR for newly diagnosed SSTR‑positive advanced GEP‑NET

  This trial will test whether adding [177Lu]Lu‑DOTA‑TATE to octreotide LAR helps people newly diagnosed with somatostatin receptor–positive, well‑differentiated (G1/G2, Ki‑67 <10%) advanced gastroenteropancreatic neuroendocrine tumors who have a high disease burden.

  Recruiting at 66 sites Phase 3 Novartis · Scottsdale, Arizona and 66 other locations · NCT06784752

• Combining Lutathera® and Olaparib for treating recurrent solid tumors in children and adolescents

  This study is testing if combining Lutathera® with olaparib can help children and teenagers with hard-to-treat solid tumors that have certain receptors.

  Recruiting Phase 1/2 Fundación de investigación HM · Boadilla del Monte, Madrid · NCT06607692

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.